EarCentric EX2 vs Otofonix Groove

The EarCentric EX2 is a behind-the-ear prescription hearing aid priced at $218, positioning it as a budget-friendly option in the prescription category. In HearAdvisor's lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking #35 of 39 prescription hearing aids tested. This 2021 release demonstrates mixed performance across key metrics. Its standout strength is feedback handling, scoring an excellent 4.7/5—essentially matching the category average and indicating reliable stability during movement. However, speech performance is a significant weakness: speech in quiet scores just 1.0/5 (2.40 points below the category average of 3.40), and speech in noise scores 1.0/5 (1.11 points below average). These low absolute scores suggest limited audibility enhancement in our standardized test conditions. Own-voice comfort scores 2.3/5, which is mixed in absolute terms and 0.40 points below the category average. Music streaming scored 0.0/5, indicating this device is not suited for audio entertainment purposes. The EarCentric EX2 may appeal to budget-conscious consumers who prioritize cost over performance, but alternatives exist at similar or lower price points with stronger test results. The RxEars Rxi, available in the same price range, scored 4.07/5 in our testing. Consumers seeking entry-level amplification should weigh the significant speech clarity limitations against the low purchase price.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE ranks #38 of 39 devices in the prescription hearing aid category, placing it in the bottom 5% of its class. In our testing, the Groove demonstrated excellent feedback handling at 5.0/5, scoring 0.28 points above the category average. This represents a genuine strength, with the device maintaining stability during our standardized challenge motions. However, speech performance was significantly limited, with speech in quiet scoring 1.0/5 (2.40 points below the category average of 3.40) and speech in noise also at 1.0/5 (1.11 points below average). Music streaming was not functional in our tests, scoring 0.0/5 against a category average of 2.76. Own-voice comfort also fell well below typical prescription hearing aid performance at 0.4/5, which is 2.30 points below the category average. At this price point, several lower-cost alternatives delivered stronger overall performance in our testing. Consumers seeking value in the prescription category may want to explore other options, though those requiring robust feedback control in a rechargeable BTE format may find the Groove's stability noteworthy despite its other limitations.